162 related articles for article (PubMed ID: 19934298)
1. Targeting the RET pathway in thyroid cancer.
Wells SA; Santoro M
Clin Cancer Res; 2009 Dec; 15(23):7119-23. PubMed ID: 19934298
[TBL] [Abstract][Full Text] [Related]
2. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
[TBL] [Abstract][Full Text] [Related]
3. [Neural crest and multiple endocrinopathies].
Pasini A; Michiels FM; Chappuis-Flament S; Geneste O; Rossel M; Fournier L; Feunteun J; Lenoir G; Schuffenecker I; Billaud M
C R Seances Soc Biol Fil; 1996; 190(5-6):557-67. PubMed ID: 9074721
[TBL] [Abstract][Full Text] [Related]
4. An in-frame complex germline mutation in the juxtamembrane intracellular domain causing RET activation in familial medullary thyroid carcinoma.
Cordella D; Muzza M; Alberti L; Colombo P; Travaglini P; Beck-Peccoz P; Fugazzola L; Persani L
Endocr Relat Cancer; 2006 Sep; 13(3):945-53. PubMed ID: 16954442
[TBL] [Abstract][Full Text] [Related]
5. RET receptor signaling: dysfunction in thyroid cancer and Hirschsprung's disease.
Asai N; Jijiwa M; Enomoto A; Kawai K; Maeda K; Ichiahara M; Murakumo Y; Takahashi M
Pathol Int; 2006 Apr; 56(4):164-72. PubMed ID: 16634961
[TBL] [Abstract][Full Text] [Related]
6. RET proto-oncogene mutations are restricted to codons 634 and 918 in mainland Chinese families with MEN2A and MEN2B.
Zhou Y; Zhao Y; Cui B; Gu L; Zhu S; Li J; Liu J; Yin M; Zhao T; Yin Z; Yu C; Chen C; Wang L; Xiao B; Hong J; Zhang Y; Tang Z; Wang S; Li X; Ning G
Clin Endocrinol (Oxf); 2007 Oct; 67(4):570-6. PubMed ID: 17573899
[TBL] [Abstract][Full Text] [Related]
7. Neurotrophic factor receptor RET: structure, cell biology, and inherited diseases.
Runeberg-Roos P; Saarma M
Ann Med; 2007; 39(8):572-80. PubMed ID: 17934909
[TBL] [Abstract][Full Text] [Related]
8. Diversity of mutations in the RET proto-oncogene and its oncogenic mechanism in medullary thyroid cancer.
Hedayati M; Zarif Yeganeh M; Sheikholeslami S; Afsari F
Crit Rev Clin Lab Sci; 2016 Aug; 53(4):217-27. PubMed ID: 26678667
[TBL] [Abstract][Full Text] [Related]
9. Targeting RET receptor tyrosine kinase activation in cancer.
Phay JE; Shah MH
Clin Cancer Res; 2010 Dec; 16(24):5936-41. PubMed ID: 20930041
[TBL] [Abstract][Full Text] [Related]
10. The multiple endocrine neoplasia syndromes.
Lakhani VT; You YN; Wells SA
Annu Rev Med; 2007; 58():253-65. PubMed ID: 17037976
[TBL] [Abstract][Full Text] [Related]
11. The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins.
Iervolino A; Iuliano R; Trapasso F; Viglietto G; Melillo RM; Carlomagno F; Santoro M; Fusco A
Cancer Res; 2006 Jun; 66(12):6280-7. PubMed ID: 16778204
[TBL] [Abstract][Full Text] [Related]
12. SH2B1beta adaptor is a key enhancer of RET tyrosine kinase signaling.
Donatello S; Fiorino A; Degl'Innocenti D; Alberti L; Miranda C; Gorla L; Bongarzone I; Rizzetti MG; Pierotti MA; Borrello MG
Oncogene; 2007 Oct; 26(45):6546-59. PubMed ID: 17471236
[TBL] [Abstract][Full Text] [Related]
13. Roles of induced expression of MAPK phosphatase-2 in tumor development in RET-MEN2A transgenic mice.
Hasegawa T; Enomoto A; Kato T; Kawai K; Miyamoto R; Jijiwa M; Ichihara M; Ishida M; Asai N; Murakumo Y; Ohara K; Niwa Y; Goto H; Takahashi M
Oncogene; 2008 Sep; 27(43):5684-95. PubMed ID: 18542059
[TBL] [Abstract][Full Text] [Related]
14. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors.
de Groot JW; Links TP; Plukker JT; Lips CJ; Hofstra RM
Endocr Rev; 2006 Aug; 27(5):535-60. PubMed ID: 16849421
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of Disease: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy.
Drosten M; Pützer BM
Nat Clin Pract Oncol; 2006 Oct; 3(10):564-74. PubMed ID: 17019434
[TBL] [Abstract][Full Text] [Related]
16. Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers.
Roskoski R; Sadeghi-Nejad A
Pharmacol Res; 2018 Feb; 128():1-17. PubMed ID: 29284153
[TBL] [Abstract][Full Text] [Related]
17. RET-mediated modulation of tumor microenvironment and immune response in multiple endocrine neoplasia type 2 (MEN2).
Castellone MD; Melillo RM
Endocr Relat Cancer; 2018 Feb; 25(2):T105-T119. PubMed ID: 28931560
[TBL] [Abstract][Full Text] [Related]
18. RET inhibition: implications in cancer therapy.
Borrello MG; Ardini E; Locati LD; Greco A; Licitra L; Pierotti MA
Expert Opin Ther Targets; 2013 Apr; 17(4):403-19. PubMed ID: 23461584
[TBL] [Abstract][Full Text] [Related]
19. A rapid method for the purification of wild-type and V804M mutant ret catalytic domain: A tool to study thyroid cancer.
Sala E; Mologni L; Cazzaniga S; Papinutto E; Gambacorti-Passerini C
Int J Biol Macromol; 2006 Aug; 39(1-3):60-5. PubMed ID: 16490247
[TBL] [Abstract][Full Text] [Related]
20. RET Regulates Human Medullary Thyroid Cancer Cell Proliferation through CDK5 and STAT3 Activation.
Yue CH; Oner M; Chiu CY; Chen MC; Teng CL; Wang HY; Hsieh JT; Lai CH; Lin H
Biomolecules; 2021 Jun; 11(6):. PubMed ID: 34207842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
